As I've posted many times - Europe is years away.
Read the last paragraph, facts are facts. Hexo bought Zenabis - as they stated many times - to gain 'immediate access to Europe'.
Another case of a complete lack of due diligence and research by SSL.
Zenabis, like Newstrike, was a bad business decision
Another MSO, Columbia Care Inc. (CCHW), lost eight cents to $6.86 on 270,800 shares. While it had no glitzy partnerships or rebrandings to announce today, it did trumpet a "huge win" -- specifically, the appointment of new director Julie Hill. Ms. Hill's resume is a ticker tape of disparate roles. They include a marketing position at Mobil Oil, president and CEO of real estate developer Costain Homes, founder of The Hill Company (with a portfolio of interests), former director of health insurance provider Anthem, and current director of the Lord Abbett Family of Funds (a $225-billion mutual fund management firm). Ms. Hill made some non-corporate headlines in 2019, after reserving a $200,000 (U.S.) ticket to become an "astro-tourist" on one of Virgin Galactic's eventual commercial space flights. (She got a good deal; tickets these days are around $400,000 (U.S.). Virgin Galactic owner Sir Richard Branson -- reportedly a friend of Ms. Hill's -- recently told the British press that the company is hoping to start running the flights later this year.)
Columbia Care appears to be Ms. Hill's first dabble in the cannabis industry. CEO Nicholas Vita dubbed himself "thrilled" to welcome her to the board, lauding her "extensive experience" and "unique and insightful lens." He is no doubt especially thrilled by her extensive network, particularly in Europe. Although Columbia Care does virtually all of its business in the United States, it has said it is "exploring opportunities in the United Kingdom and Germany, as well as other markets within the EU." In April, through a partnership with two U.K. pharmaceutical companies, Columbia Care launched the first medical cannabis capsules in the U.K. market. (The more common medical cannabis products in this market are flower and tinctures.)
Columbia Care is not the first MSO to signal an interest in Europe. In March, the above-mentioned Curaleaf paid $286-million (U.S.) for the London-based EMMAC Life Sciences. As many of the numerous Canadian cannabis companies that established and then retreated from European beachheads over the last few years discovered, this market is still in its infancy and will likely take years to show significant revenue contributions. The London-based cannabis consultancy Prohibition Partners recently figured that the entire European cannabis market took in a scant $300-million (U.S.) in 2020. Over time, however, Prohibition Partners -- and presumably the companies now starting to eye Europe -- can see this figure rising to $2.5-billion (U.S.), perhaps as soon as 2024.